Compare Sun Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA JUBILANT LIFE SCIENCES SUN PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 28.5 14.6 195.4% View Chart
P/BV x 2.5 1.7 144.5% View Chart
Dividend Yield % 0.6 0.9 74.2%  

Financials

 SUN PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
SUN PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs679898 75.6%   
Low Rs375618 60.8%   
Sales per share (Unadj.) Rs121.1572.0 21.2%  
Earnings per share (Unadj.) Rs13.436.2 36.9%  
Cash flow per share (Unadj.) Rs20.759.5 34.8%  
Dividends per share (Unadj.) Rs2.754.50 61.1%  
Dividend yield (eoy) %0.50.6 87.9%  
Book value per share (Unadj.) Rs172.6301.9 57.2%  
Shares outstanding (eoy) m2,399.26159.28 1,506.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.3 328.4%   
Avg P/E ratio x39.420.9 188.4%  
P/CF ratio (eoy) x25.512.7 200.1%  
Price / Book Value ratio x3.12.5 121.7%  
Dividend payout %20.612.4 165.5%   
Avg Mkt Cap Rs m1,264,650120,694 1,047.8%   
No. of employees `00017.52.4 732.3%   
Total wages/salary Rs m59,67119,260 309.8%   
Avg. sales/employee Rs Th16,608.138,120.6 43.6%   
Avg. wages/employee Rs Th3,409.68,058.4 42.3%   
Avg. net profit/employee Rs Th1,833.82,414.3 76.0%   
INCOME DATA
Net Sales Rs m290,65991,108 319.0%  
Other income Rs m10,255357 2,869.3%   
Total revenues Rs m300,91491,466 329.0%   
Gross profit Rs m63,07617,390 362.7%  
Depreciation Rs m17,5333,709 472.7%   
Interest Rs m5,5532,198 252.6%   
Profit before tax Rs m50,24611,840 424.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,144-2,802 433.4%   
Tax Rs m6,0093,268 183.9%   
Profit after tax Rs m32,0935,770 556.2%  
Gross profit margin %21.719.1 113.7%  
Effective tax rate %12.027.6 43.3%   
Net profit margin %11.06.3 174.3%  
BALANCE SHEET DATA
Current assets Rs m310,69245,848 677.7%   
Current liabilities Rs m173,39620,897 829.8%   
Net working cap to sales %47.227.4 172.5%  
Current ratio x1.82.2 81.7%  
Inventory Days Days9957 174.4%  
Debtors Days Days11251 219.0%  
Net fixed assets Rs m232,47765,498 354.9%   
Share capital Rs m2,399159 1,506.2%   
"Free" reserves Rs m411,69147,930 858.9%   
Net worth Rs m414,09148,089 861.1%   
Long term debt Rs m15,22642,429 35.9%   
Total assets Rs m646,938114,685 564.1%  
Interest coverage x10.06.4 157.3%   
Debt to equity ratio x00.9 4.2%  
Sales to assets ratio x0.40.8 56.6%   
Return on assets %5.86.9 83.8%  
Return on equity %7.812.0 64.6%  
Return on capital %10.212.4 81.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02512,422 531.5%   
Fx outflow Rs m38,61017,227 224.1%   
Net fx Rs m27,415-4,805 -570.6%   
CASH FLOW
From Operations Rs m21,96511,215 195.8%  
From Investments Rs m-6,813-10,118 67.3%  
From Financial Activity Rs m-27,3056,574 -415.3%  
Net Cashflow Rs m-8,4427,612 -110.9%  

Share Holding

Indian Promoters % 63.7 45.6 139.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 5.1 8.7 59.0%  
FIIs % 23.0 21.2 108.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.1 39.3%  
Shareholders   133,026 23,815 558.6%  
Pledged promoter(s) holding % 0.5 15.9 3.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 13, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS